Lupin

Lupin Ltd, on September 27, 2007 has announced that it has acquired Rubamin Laboratories Ltd (RLL), a part of the Rubamin group. The pharmaceutical business of Rubamin group was operated through its subsidiary RLL, largely engaged in the manufacture of advanced intermediates for APIs under Contract Research And Manufacturing (CRAMS) model.

RLL has over a decade of experience in manufacturing advanced intermediates for APIs. RLL today has capabilities to participate in the value chain from drug development to commercial production of advanced intermediates for APIs. RLL has built a strong customer base and with Company's strengths will be in a better position to support the global pharmaceutical industry.

Dr. Desh Bandhu Gupta, Chairman of the Company said, "We are delighted at this acquisition. It enables us to step up our strategic initiative in the CRAMS segment. We have a proven track record of achieving global position in every therapy that we have entered at intermediate and API level. We are looking forward to replicate our success in this field as well."